Fiera Capital Corp Sells 2,448 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Fiera Capital Corp reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 2.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 116,942 shares of the biotechnology company’s stock after selling 2,448 shares during the quarter. Fiera Capital Corp’s holdings in Exelixis were worth $2,805,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EXEL. Acadian Asset Management LLC raised its stake in shares of Exelixis by 1,043.9% in the third quarter. Acadian Asset Management LLC now owns 1,957,848 shares of the biotechnology company’s stock worth $42,750,000 after buying an additional 1,786,687 shares during the period. abrdn plc purchased a new stake in shares of Exelixis in the fourth quarter worth $15,997,000. California Public Employees Retirement System raised its position in shares of Exelixis by 42.3% during the 3rd quarter. California Public Employees Retirement System now owns 1,771,128 shares of the biotechnology company’s stock valued at $38,699,000 after purchasing an additional 526,814 shares during the period. NewEdge Wealth LLC purchased a new position in shares of Exelixis during the 3rd quarter valued at $10,238,000. Finally, Braun Stacey Associates Inc. bought a new position in Exelixis in the 4th quarter worth $10,414,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Down 1.5 %

EXEL opened at $20.91 on Friday. The business has a fifty day moving average of $22.84 and a 200 day moving average of $22.29. Exelixis, Inc. has a 52-week low of $18.64 and a 52-week high of $24.34. The stock has a market cap of $6.34 billion, a P/E ratio of 32.67, a PEG ratio of 0.57 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The company had revenue of $425.23 million during the quarter, compared to the consensus estimate of $461.04 million. During the same quarter in the previous year, the company posted $0.12 earnings per share. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. Equities analysts anticipate that Exelixis, Inc. will post 1.16 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director David Edward Johnson bought 190,000 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were bought at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the purchase, the director now directly owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Jack L. Wyszomierski sold 10,923 shares of Exelixis stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $21.37, for a total value of $233,424.51. Following the completion of the sale, the director now directly owns 338,948 shares in the company, valued at approximately $7,243,318.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Edward Johnson purchased 190,000 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were bought at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the purchase, the director now directly owns 1,100,730 shares in the company, valued at approximately $22,785,111. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 77,148 shares of company stock worth $1,703,116. 2.85% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Barclays cut Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target on the stock. in a report on Thursday, April 11th. JMP Securities restated a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research note on Wednesday, April 10th. TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. Royal Bank of Canada boosted their target price on shares of Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Finally, TD Cowen raised their target price on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Seven equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average target price of $26.13.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.